Gene-modified immune cells for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) that has grown despite standard treatments like chemotherapy or immunotherapy.
- You have at least one tumor that can be measured on scans (like a CT scan).
- You have a stored tumor sample or are willing to have a new biopsy to check for certain markers on your cancer cells.
- Your cancer cells must show high levels of at least two of these markers: MSLN, EGFR, or HER2.
- You are able to do your daily activities with little or no help (performance status 0 or 1).
- You do not have uncontrolled brain metastases, severe lung disease, or a history of severe reactions to earlier cell therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.